Pharmosa Biopharm Inc. (TPEX:6875)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
36.30
+0.85 (2.40%)
May 29, 2026, 1:30 PM CST
Market Cap4.69B -30.7%
Revenue (ttm)69.06M -58.8%
Net Income-385.09M
EPS-2.98
Shares Out 129.15M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume141,418
Open37.00
Previous Close35.45
Day's Range35.60 - 37.00
52-Week Range34.05 - 65.00
Beta0.19
Analystsn/a
Price Targetn/a
Earnings DateAug 14, 2026

About Pharmosa Biopharm

Pharmosa Biopharm Inc., a biotechnology company, focuses on developing drugs in Taiwan. It develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease. The company was formerly known as Pharmosa Limited and changed its name to Pharmosa Biopharm Inc. in October 2016. Pharmosa Biopharm Inc. was founded in 2000 and is headquartered in Taipei, Taiwan... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6875
Full Company Profile

Financial Performance

In 2025, Pharmosa Biopharm's revenue was 67.27 million, a decrease of -59.86% compared to the previous year's 167.57 million. Losses were -383.85 million, 130.3% more than in 2024.

Financial Statements